AU Patent

AU2024287122A1 — Formulations/compositions comprising ibrutinib

Assigned to Janssen Pharmaceutica NV · Expires 2025-01-23 · 1y expired

What this patent protects

FORMULATIONS/COMPOSITIONS COMPRISING IBRUTINIB 5 Disclosed are formulations/compositions comprising ibrutinib: NH 2 N . N KN N' N 0 as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use…

USPTO Abstract

FORMULATIONS/COMPOSITIONS COMPRISING IBRUTINIB 5 Disclosed are formulations/compositions comprising ibrutinib: NH 2 N . N KN N' N 0 as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such 10 formulations/compositions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024287122A1
Jurisdiction
AU
Classification
—
Expires
2025-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.